InvestorsHub Logo
Followers 22
Posts 996
Boards Moderated 0
Alias Born 08/01/2016

Re: None

Monday, 09/26/2016 4:00:05 PM

Monday, September 26, 2016 4:00:05 PM

Post# of 3058
Summit's (SMMT) drug received fast-track status, which will dramatically speed the review process. They are currently trading just above $100 million market capitalization but could easily run to $1B (a 10x gain) before they file for NDA. Recall that SRPT reached about $1.5B before approval and eteplirsen only addresses 13% of the DMD population, whereas Summit's drug is intended for the entire DMD population !!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRPT News